

WRL  
12-7-00

REC

12-07-2000

ET



101543581

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof

1. Name of conveying party(ies):

Micky D. Tortorella

Additional names of conveying parties attached? ☐ Yes ☒ No

2. Name and address of receiving party(ies):

Name: DuPont Pharmaceuticals Company

Address: Chestnut Run Plaza, 974 Centre Road  
Wilmington, Delaware 19805

Additional name(s) & address(es) attached? ☐ Yes ☒ No

3. Nature of conveyance:

- ☒ Assignment ☐ Merger  
☐ Security Agreement ☐ Change of Name  
☐ Other \_\_\_\_\_

Execution date: April 18, 2000

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s)  
09/540,030

B. Patent No.(s):

Additional numbers attached? ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning this document should be mailed:

Kevin S. Lemack  
Nields, Lemack & Dingman  
176 East Main Street, Suite 8  
Westborough, MA 01581

6. Total number of applications and patents involved: 1

7. Total fee (37 CFR 3.41): \$40.00

- ☒ Enclosed  
☐ Authorized to be charged to deposit account

8. Deposit account number: 14-0930

DO NOT USE THIS SPACE

09/18/2000 JJALLAH2 00000004 09540030

01 FC:581

40.00 0P

9. Statement and signature.

*To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.*

Kevin S. Lemack

Name of person signing

Signature

Date

8/14/00

Attorney Docket No.: PH-7162 (MCA-520-2)

Total number of pages including cover sheet, attachments and document: 2

# PATENT APPLICATION ASSIGNMENT

We, the undersigned

Hereby declare that

We are the true and first inventors of an invention entitled **Novel Filtrate Plate Device and Reversible-Well Plate Device** (and which is identified as Case Number **PH-7162**) and which is disclosed in an application for Letters Patent in the United States of America.

For valuable consideration, the receipt and adequacy of which is hereby acknowledged and in fulfillment of our pre-existing obligation of assignment, we hereby:

I. Sell, assign, and transfer unto **DuPont Pharmaceuticals Company**, a General Partnership organized and existing under the laws of the State of Delaware in the United States of America and having its principal place of business at Chestnut Run Plaza, 974 Centre Road, Wilmington, Delaware 19805, hereinafter referred to as the assignee, (A). the sole and entire right, and interest in and to: (1) the aforesaid application for Letters Patent, (2) any priority rights derived from the aforesaid application for Letters Patent by virtue of intellectual property for any and all member countries of the aforesaid International Convention or other treaty or understanding, (3) any and all of our inventions, whether joint or sole, disclosed in the aforesaid application for Letters Patent, (4) any and all applications for Letters Patent for any such inventions in any country whatsoever, (5) any and all patents for any such inventions in any country whatsoever; and (B) the sole right to (1) file such applications in its name or ours, (2) file such applications under the aforesaid International Convention or other treaty or understanding, (3) have said patents granted in its name or ours, and (4) enforce said patents and to sue for and recover profits and damages for any and all infringements thereof whether past or future; and

II. Agree, whenever requested, to communicate to said assignee, its successors, assigns, and legal representatives, any facts known to us respecting said rights, to testify in any legal proceeding respecting said rights, to execute all applications, papers or instruments necessary or required by said assignee, its successors, assigns and legal representatives, to carry into effect any of the provisions of this instrument, and generally to do everything possible to aid said assignee, its successors, assigns, and legal representatives to obtain and enforce proper patent protection for said inventions in any and all countries.

We further authorize our attorney/patent agent to insert below\* the application number and filing date of the aforesaid United States application now identified as Case Number. After the same shall have been made known to him/her by the United States Patent Office.

Date: 04/18/00

Micky D. Tortorella (L.S.)  
Micky D. Tortorella

Date: \_\_\_\_\_

\_\_\_\_\_  
(L.S.)

Date: \_\_\_\_\_

\_\_\_\_\_  
(L.S.)

Date: \_\_\_\_\_

\_\_\_\_\_  
(L.S.)

Date: \_\_\_\_\_

\_\_\_\_\_  
(L.S.)

Date: \_\_\_\_\_

\_\_\_\_\_  
(L.S.)

Date: \_\_\_\_\_

\_\_\_\_\_  
(L.S.)

Date: \_\_\_\_\_

\_\_\_\_\_  
(L.S.)

\*The application referred to above (Case No. **PH-7162**) was filed in the United States Patent Office on March 31, 2000, and was given Application No. 09/540,030.  
This insertion made by me this 4th day of August, 2000.

Kenneth B. Rubin  
Kenneth B. Rubin  
Registration No. 36,259